[Hemodynamic effects of intravenous omeprazole in critically ill children]

M J Solana1, J López-Herce, M Botrán

  • 1Unidad de Cuidados Intensivos Pediátricos, Hospital General Universitario Gregorio Marañón, Madrid, España.

Insights

Intravenous omeprazole is safe for critically ill children, showing no significant hemodynamic changes in a study comparing two doses. This finding supports its use for gastrointestinal bleeding prophylaxis in pediatric intensive care units.

Area of Science:

  • Pediatric Critical Care Medicine
  • Pharmacology
  • Cardiovascular Physiology

Background:

  • Critically ill children often experience hemodynamic instability.
  • Omeprazole is used for gastrointestinal bleeding prophylaxis but its cardiovascular effects are unknown.
  • This study investigates the hemodynamic impact of intravenous omeprazole in pediatric patients.

Purpose of the Study:

  • To assess hemodynamic changes following intravenous omeprazole administration in critically ill children.
  • To compare the effects of two different intravenous omeprazole doses (0.5mg/kg vs. 1mg/kg).

Main Methods:

  • A randomized prospective study involved 37 critically ill children (1 month to 14 years).
  • Participants received either 0.5mg/kg or 1mg/kg intravenous omeprazole over 20 minutes.
  • Hemodynamic parameters (heart rate, blood pressure, central venous pressure) and ECG were monitored before and after infusion.

Main Results:

  • No significant changes were observed in heart rate, blood pressure, or central venous pressure.
  • Electrocardiogram findings remained stable throughout the study period.
  • No dose-dependent differences or need for inotropic support modification were noted between the two omeprazole groups.

Conclusions:

  • Intravenous omeprazole at both 0.5mg/kg and 1mg/kg is hemodynamically safe in critically ill children.
  • The drug can be safely administered for gastrointestinal bleeding prophylaxis without adverse cardiovascular effects.
  • Findings support the use of intravenous omeprazole in pediatric intensive care settings.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...